男子淋菌性尿道炎に対するLevofloxacinの細菌学的・臨床的検討

Abstract

淋菌に対するLVFXの抗菌力は≦0.003 μg/ml～0.39 μg/mlに分布, MIC50 0.0125 μg/ml, MIC90 0.1 μg/mlでありCPFX, TFLX, SPFX, FLRX, OFLXとほぼ同程度であり, NFLX, ENX, LFLXと比べやや優れていた.PPNGに対する抗菌力はnon-PPNGと比べ差はなくβ-lactamaseに対する安定性を認めた.臨床的有用性については対象10例中, LVFXを1回200 mg, 1日2回を8例に, 1回100 mg, 1日2回を2例に, いずれも3日間投与した.総合有効率は著効4例, 有効4例であった.Chlamydia trachomatis(クラミジア)混合感染例は2例あり, ともに有効であった.副作用の発現はなかった

We performed basic and clinical studies in male gonococcal urethritis on a new oral antimicrobial agent, levofloxacin (LVFX, DR-3355), a new quinolone derivative. The antibacterial activity of LVFX against clinical strains of Neisseria gonorrhoeae was roughly comparable to that of ofloxacin, and ciprofloxacin. LVFX was administered to 10 males with gonococcal urethritis, 200 mg twice a day (8 cases) or 100 mg twice a day for 3 days (2 cases). Clinical evaluation was made according to the criteria of the Japanese UTI Committee. Overall efficacy rate was 100% (10/10). In the complication of chlamydia trachomatis (2 cases), efficacy rate was 100% (2/2). No subjective or objective adverse reactions occurred.